Senexin C

Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability[1].

Product Specifications

CAS Number

[2375554-02-0]

UNSPSC

12352005

Target

CDK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/senexin-c.html

Purity

98.82

Solubility

DMSO : 33.33 mg/mL (ultrasonic; warming; adjust pH to 2 with 1M HCl; heat to 160°C)

Smiles

N#CC1=CC=C2N=CC=C(NCCC3=CC=C4C=C(C(N5CCN(C)CC5)=O)C=CC4=C3)C2=C1

Molecular Formula

C28H27N5O

Molecular Weight

449.55

References & Citations

[1]Zhang L, et al. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. J Med Chem. 2022; 65 (4) :3420-3433.